Profile data is unavailable for this security.
About the company
Xlife Sciences AG is a Switzerland-based biotechnology company. The Company focuses on investing in technologies in the life science industry. It supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The Company offers its investors direct access to the further development of technologies at a very early stage. The Company cooperates with industrial partners and universities.
- Revenue in CHF (TTM)1.00m
- Net income in CHF16.13m
- Incorporated2013
- Employees19.00
- LocationXlife Sciences AGTalacker 35ZUERICH 8001SwitzerlandCHE
- Phone+41 443858460
- Websitehttps://www.xlifesciences.ch/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Partners AG | 7.04m | -61.98m | 116.38m | 168.00 | -- | 0.5959 | -- | 16.54 | -1.89 | -1.89 | 0.2147 | 5.37 | 0.0306 | -- | 4.74 | 41,892.86 | -26.91 | -11.83 | -28.90 | -14.69 | -- | 99.28 | -880.70 | -45.30 | -- | -70.97 | 0.0203 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
Santhera Pharmaceuticals Holding AG | 5.16m | -64.69m | 119.94m | 46.00 | -- | -- | -- | 23.23 | -27.26 | -27.26 | 1.35 | -4.65 | 0.0723 | 34.23 | 3.54 | 112,217.40 | -90.56 | -54.38 | -250.35 | -75.34 | 29.39 | 78.16 | -1,253.16 | -209.10 | 0.0778 | -2.29 | -- | -- | 568.53 | -20.10 | -27.87 | -- | 23.14 | -- |
Newron Pharmaceuticals SpA | 8.86m | -15.87m | 124.62m | 23.00 | -- | -- | -- | 14.06 | -0.8896 | -0.8896 | 0.4966 | -1.64 | 0.2873 | -- | 4.57 | 385,311.70 | -51.45 | -37.10 | -111.53 | -43.98 | 94.80 | 91.72 | -179.13 | -270.48 | -- | -2.86 | 2.62 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
Xlife Sciences AG | 1.00m | 16.13m | 195.62m | 19.00 | 27.18 | 0.8077 | 7.34 | 194.94 | 1.26 | 1.26 | 0.1368 | 42.47 | 0.0021 | -- | 1.68 | 52,815.79 | 2.25 | -- | 2.88 | -- | 30.17 | -- | 1,062.47 | -- | -- | -- | 0.1437 | -- | 27.53 | -- | -73.21 | -- | -- | -- |
Kuros Biosciences AG | 33.56m | -13.73m | 254.01m | 80.00 | -- | 4.47 | -- | 7.57 | -0.3697 | -0.3697 | 0.9175 | 1.54 | 0.4347 | 2.40 | 7.27 | 419,550.00 | -17.78 | -13.47 | -21.34 | -14.84 | 71.31 | 78.73 | -40.90 | -81.48 | 1.69 | -84.04 | 0.0364 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
Idorsia Ltd | 184.69m | -374.06m | 328.97m | 1.36k | -- | -- | -- | 1.78 | -2.11 | -2.11 | 1.04 | -4.65 | 0.2201 | 0.2374 | 62.89 | 135,698.00 | -44.59 | -43.40 | -62.30 | -48.06 | 94.92 | -- | -202.54 | -966.50 | 1.02 | -26.39 | 3.77 | -- | 174.70 | -9.29 | -30.46 | -- | 28.72 | -- |
Basilea Pharmaceutica AG Allschwil | 157.63m | 10.45m | 527.33m | 147.00 | 45.92 | -- | 43.76 | 3.35 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
Polypeptide Group AG | 317.86m | -50.33m | 955.48m | 1.20k | -- | 2.55 | -- | 3.01 | -1.52 | -1.52 | 9.60 | 11.31 | 0.5137 | 2.31 | 5.08 | 264,446.60 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
Data as of Apr 25 2024. Currency figures normalised to Xlife Sciences AG's reporting currency: Swiss Franc CHF
Holder | Shares | % Held |
---|---|---|
Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 31.72k | 0.56% |
UBS Asset Management Switzerland AGas of 02 Apr 2024 | 22.36k | 0.39% |
Z�rcher Kantonalbank (Investment Management)as of 29 Feb 2024 | 12.69k | 0.22% |
OFZL AGas of 31 Mar 2023 | 10.00k | 0.18% |
CATAM Asset Management AGas of 31 Mar 2021 | 8.00k | 0.14% |
Pictet Asset Management SAas of 31 Dec 2023 | 5.97k | 0.11% |
BlackRock Asset Management Schweiz AGas of 04 Apr 2024 | 5.25k | 0.09% |
Credit Suisse AGas of 31 Jan 2024 | 3.41k | 0.06% |
Belvoir Capital AGas of 31 Oct 2023 | 2.36k | 0.04% |
Gutmann Finanz Strategien AGas of 31 Dec 2023 | 2.05k | 0.04% |
More ▼
Data from 31 Mar 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.